Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Thoracic 1Myeloid 1Genitourinary 1Classical hematology 1CNS 1

Conditions

Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Hematologic Neoplasms 1Anemia, Aplastic 1

Interventions

fludarabine phosphate 15Whole-Body Irradiation 9Peripheral Blood Stem Cell Transplantation 8Mycophenolic Acid 8Cyclosporine 8Cyclophosphamide 7Tacrolimus 5Filgrastim 5Cytarabine 5Carboplatin 4Azacitidine 4olaparib 3Thiotepa 3Lenalidomide 3Etoposide 3Bortezomib 3Biopsy 3Antilymphocyte Serum 3venetoclax 2tipifarnib 2sargramostim 2peginesatide 2laromustine 2hematide 2enasidenib 2alvocidib 2aldesleukin 2Vorinostat 2Tretinoin 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Practice Guidelines as Topic × Classical hematology × Clear all
NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
10 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡